sur Andera Partners
Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom
Andera Partners announced today a €63 million Series A financing round for SciRhom, a Munich-based biopharmaceutical firm. The funds will drive SciRhom’s lead development program toward clinical proof-of-concept and broaden the therapeutic impact of its iRhom2 strategy. The round includes top-tier investors such as Kurma Partners, Hadean Ventures, MIG Capital, Wellington Partners, Bayern Kapital, and existing investors like High-Tech Gründerfonds and PhiFund Ventures.
SciRhom, specializing in autoimmune disorders, aims to address various autoimmune diseases by targeting iRhom2, a key regulator in autoimmune signaling pathways. Their lead candidate, SR-878, a monoclonal antibody, will enter clinical trials in the second half of 2024 to evaluate its safety and initial clinical activity.
The new investment will support SciRhom’s Phase 1 trials, which will commence in Austria. The company has shown positive preclinical results in rheumatoid arthritis and inflammatory bowel disease models. Founders and key partners emphasize SciRhom’s potential for transformative treatments in the autoimmune sector.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Andera Partners